FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1583886228> ?p ?o ?g. }

• W1583886228 endingPage "907" @default.
• W1583886228 startingPage "899" @default.
• W1583886228 abstract "BACKGROUND: We assessed the efficacy of taxane chemotherapy in BRCA1- and BRCA2-associated patients compared with sporadic metastatic breast cancer patients. METHODS: Response rates (RRs) to and progression-free survival (PFS) after taxane chemotherapy of 35 BRCA1-associated and 13 BRCA2-associated metastatic breast cancer patients were compared with those outcomes in 95 matched (1:2) sporadic patients. Matching was performed for age at and year of diagnosis of primary breast cancer, year of metastatic disease, and line of therapy (first vs second or third). RESULTS: Among BRCA1-associated patients, the RR was worse (objective response [OR], 23% vs 38%; progressive disease [PD], 60% vs 19%; P < 0.001); and the median PFS shorter (2.2 vs 4.9 months; P = 0.04) compared with sporadic patients. In the subgroup of hormone receptor (HRec)-negative patients, BRCA1-associated patients (n = 20) had a worse RR (OR, 20% vs 42%, respectively; PD, 70% vs 26%, respectively; P = 0.03) and a shorter PFS (1.8 vs 3.8 months; P = 0.004) compared with sporadic patients (n = 19). These outcomes in HRec-positive patients were similar in BRCA1-associated (n = 11) and sporadic (n = 61) patients (OR, 36% vs 38%; PD, 28% vs 20%; median PFS, both 5.7 months). In BRCA2-associated patients, who were mainly HRec-positive, the OR was higher than in sporadic patients (89% vs 38%, respectively; P = 0.02), whereas the median PFS was not significantly different (7.1 vs 5.7 months, respectively). CONCLUSIONS: BRCA1-associated, HRec-negative metastatic breast cancer patients were less sensitive to taxane chemotherapy than sporadic HRec-negative patients. HRec-positive BRCA1- and BRCA2-associated patients had a sensitivity to taxane chemotherapy similar to that of sporadic patients. Cancer 2012;. © 2011 American Cancer Society." @default.
• W1583886228 created "2016-06-24" @default.
• W1583886228 creator A5024018573 @default.
• W1583886228 creator A5028311501 @default.
• W1583886228 creator A5035997627 @default.
• W1583886228 creator A5040594661 @default.
• W1583886228 creator A5040712804 @default.
• W1583886228 creator A5046505775 @default.
• W1583886228 creator A5064453966 @default.
• W1583886228 creator A5066926133 @default.
• W1583886228 creator A5068217711 @default.
• W1583886228 creator A5071754639 @default.
• W1583886228 creator A5082393642 @default.
• W1583886228 date "2011-07-14" @default.
• W1583886228 modified "2023-10-17" @default.
• W1583886228 title "The efficacy of taxane chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers" @default.
• W1583886228 cites W1961026612 @default.
• W1583886228 cites W1983081876 @default.
• W1583886228 cites W1984998883 @default.
• W1583886228 cites W1989643385 @default.
• W1583886228 cites W1992015449 @default.
• W1583886228 cites W1996457137 @default.
• W1583886228 cites W2017937144 @default.
• W1583886228 cites W2058681718 @default.
• W1583886228 cites W2059822676 @default.
• W1583886228 cites W2113382133 @default.
• W1583886228 cites W2114614279 @default.
• W1583886228 cites W2114709993 @default.
• W1583886228 cites W2117151785 @default.
• W1583886228 cites W2130373334 @default.
• W1583886228 cites W2146717458 @default.
• W1583886228 cites W2154824518 @default.
• W1583886228 cites W2160324074 @default.
• W1583886228 cites W2164432834 @default.
• W1583886228 cites W2166237570 @default.
• W1583886228 cites W2171972386 @default.
• W1583886228 cites W3093265161 @default.
• W1583886228 doi "https://doi.org/10.1002/cncr.26351" @default.
• W1583886228 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21761396" @default.
• W1583886228 hasPublicationYear "2011" @default.
• W1583886228 type Work @default.
• W1583886228 sameAs 1583886228 @default.
• W1583886228 citedByCount "82" @default.
• W1583886228 countsByYear W15838862282012 @default.
• W1583886228 countsByYear W15838862282013 @default.
• W1583886228 countsByYear W15838862282014 @default.
• W1583886228 countsByYear W15838862282015 @default.
• W1583886228 countsByYear W15838862282016 @default.
• W1583886228 countsByYear W15838862282017 @default.
• W1583886228 countsByYear W15838862282018 @default.
• W1583886228 countsByYear W15838862282019 @default.
• W1583886228 countsByYear W15838862282020 @default.
• W1583886228 countsByYear W15838862282021 @default.
• W1583886228 countsByYear W15838862282022 @default.
• W1583886228 countsByYear W15838862282023 @default.
• W1583886228 crossrefType "journal-article" @default.
• W1583886228 hasAuthorship W1583886228A5024018573 @default.
• W1583886228 hasAuthorship W1583886228A5028311501 @default.
• W1583886228 hasAuthorship W1583886228A5035997627 @default.
• W1583886228 hasAuthorship W1583886228A5040594661 @default.
• W1583886228 hasAuthorship W1583886228A5040712804 @default.
• W1583886228 hasAuthorship W1583886228A5046505775 @default.
• W1583886228 hasAuthorship W1583886228A5064453966 @default.
• W1583886228 hasAuthorship W1583886228A5066926133 @default.
• W1583886228 hasAuthorship W1583886228A5068217711 @default.
• W1583886228 hasAuthorship W1583886228A5071754639 @default.
• W1583886228 hasAuthorship W1583886228A5082393642 @default.
• W1583886228 hasBestOaLocation W15838862281 @default.
• W1583886228 hasConcept C121608353 @default.
• W1583886228 hasConcept C126322002 @default.
• W1583886228 hasConcept C143998085 @default.
• W1583886228 hasConcept C2775930923 @default.
• W1583886228 hasConcept C2776694085 @default.
• W1583886228 hasConcept C2776802502 @default.
• W1583886228 hasConcept C2777511904 @default.
• W1583886228 hasConcept C530470458 @default.
• W1583886228 hasConcept C71924100 @default.
• W1583886228 hasConcept C90924648 @default.
• W1583886228 hasConceptScore W1583886228C121608353 @default.
• W1583886228 hasConceptScore W1583886228C126322002 @default.
• W1583886228 hasConceptScore W1583886228C143998085 @default.
• W1583886228 hasConceptScore W1583886228C2775930923 @default.
• W1583886228 hasConceptScore W1583886228C2776694085 @default.
• W1583886228 hasConceptScore W1583886228C2776802502 @default.
• W1583886228 hasConceptScore W1583886228C2777511904 @default.
• W1583886228 hasConceptScore W1583886228C530470458 @default.
• W1583886228 hasConceptScore W1583886228C71924100 @default.
• W1583886228 hasConceptScore W1583886228C90924648 @default.
• W1583886228 hasIssue "4" @default.
• W1583886228 hasLocation W15838862281 @default.
• W1583886228 hasLocation W15838862282 @default.
• W1583886228 hasOpenAccess W1583886228 @default.
• W1583886228 hasPrimaryLocation W15838862281 @default.
• W1583886228 hasRelatedWork W181195935 @default.
• W1583886228 hasRelatedWork W1966468630 @default.
• W1583886228 hasRelatedWork W1971716849 @default.
• W1583886228 hasRelatedWork W2020150632 @default.
• W1583886228 hasRelatedWork W2062210103 @default.

• next